# A Study to Evaluate the Efficacy and Safety of Combination Therapy of BRII-179, BRII-835 and PEG-IFNα in Participants With Chronic Hepatitis B Virus (HBV) Infection (ENHANCE)

> **NCT06650852** · PHASE2 · RECRUITING · sponsor: **Brii Biosciences Limited** · enrollment: 250 (estimated)

## Conditions studied

- Chronic Hepatitis B Virus (HBV) Infection

## Interventions

- **BIOLOGICAL:** BRII-179
- **DRUG:** BRII-835 (VIR-2218)
- **BIOLOGICAL:** PEG-IFNα
- **DRUG:** Placebo of BRII-179
- **DRUG:** Placebo of BRII-835

## Key facts

- **NCT ID:** NCT06650852
- **Lead sponsor:** Brii Biosciences Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-10-31
- **Primary completion:** 2026-07
- **Final completion:** 2027-07
- **Target enrollment:** 250 (ESTIMATED)
- **Last updated:** 2025-05-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06650852

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06650852, "A Study to Evaluate the Efficacy and Safety of Combination Therapy of BRII-179, BRII-835 and PEG-IFNα in Participants With Chronic Hepatitis B Virus (HBV) Infection (ENHANCE)". Retrieved via AI Analytics 2026-07-09 from https://api.ai-analytics.org/clinical/NCT06650852. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*